-
Study aim
-
Determining the effect of two different doses of mannitol on reducing creatine phosphokinase (CPK) in brain death patients planned for organ donation
-
Design
-
A randomized, double-blinding clinical trial, with parallel groups, Phase 2 on 30 patients
-
Settings and conduct
-
In this randomized double-blind clinical trial study, 30 eligible patients referred to Al-Zahra Hospital in Isfahan will be included in the study and will be randomly divided into 2 groups. In the two groups, mannitol will be administered at a dose of 0.4 and 0.6 g/kg, respectively. The intervention will be carried out in such a way that the patient's companion and the researcher and statistical analyst will not have any knowledge of the type of intervention. Then the amount of creatine phosphokinase, blood pressure, heart rate, creatinine, sodium and potassium in the blood will be evaluated and compared between the two groups.
-
Participants/Inclusion and exclusion criteria
-
The criteria for inclusion in the study include patients with brain death, in the age group of 16 to 55 years, with confirmation of the patient's eligibility for kidney donation by the relevant team, the presence of creatine phosphokinase greater than or equal to 5000 units per liter in the initial test of the patient, and the consent of the patient's companions. It is for the purpose of linking and participating in the study. Exclusion criteria include having a pacemaker, cardiac arrest, and sepsis.
-
Intervention groups
-
First intervention group: In this group, 0.4 g/kg of mannitol along with 1 mEq of sodium bicarbonate per kilogram will be given in 20 minutes. The second intervention group: In this group, 0.6 g/kg of mannitol along with 1 mEq of sodium bicarbonate per kilogram will be given in 20 minutes.
-
Main outcome variables
-
Creatine phosphokinase; Blood pressure; Heart beat; Creatinine; Sodium; Potassium